血清胱抑素C在肝硬化、肝癌患者继发肾功能改变的研究

Studies on serum cystatin-C concentration as a marker of renal function in patients with hepatocirrhosis and hepatocellular carcinoma

目的:探讨研究血清胱抑素C(Cystatin-C CYS-C)在肝硬化、肝癌患者继发肾功能改变的意义。方法:应用德灵公司全自动特定蛋白分析仪(BN propec)采用免疫散射比浊法测定66例肝硬化、64例肝癌与62例非肝肾病的胱抑素C。结果:肝硬化组与对照组相比较,差异显著(1.25±0.51 VS 0.75±0.13,P<0.01),肝癌组与对照组比较差异不显著(0.84±0.23 VS 0.75±0.13,P>0.05),肝硬化组异常增高的百分率为70.1%,肝癌组20.3%,对照组1.61%,肝硬化、肝癌组与对照组比较差异显著(P<0.01)。结论:胱抑素C可作为肝病合并继发肾功能损伤的首选重要指标。

Objective：To investigate the serum cystatin-C concentration as a marker of renal function in patients with hepatocirrhosis and hepatocellular carcinoma.Methods：The Serum cystatin-C concentration of 66 patients with cirrhosis,64 patients with cancer and 62 healthy subjects were determined by turbidimetric immunoassay method.Results：Serum cystatin C concentrations were higher in group with cirrhosis than healthy group（1.25±0.51 VS 0.75±0.13,P〈0.01）,there was no significant difference in group with cancer and healthy group（0.84±0.23 VS 0.75±0.13,P〉0.05）.The percentage of increase Serum Cystatin-C concentrations in cirrhosis patients was 70.1%,cancer patients was 20.3%,the health was 1.61%,compared with the healthy subjects,there are significant difference（P〈0.01）.Conclusion：Serum cystatin C determination could be a valuable tool in patients with cirrhosis and cancer for early diagnosis of impaired renal function.